PREemptive Analgesia With preGABAlin in HEART Surgery
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
BACKGROUND: Postoperative pain after cardiac surgery has high incidence and is associated
with worse morbidity. Pregabalin is a new antiepileptic drug used in patients with chronic
pain and has been studied even more in postoperative. OBJECTIVE: Evaluate whether preemptive
pregabalin use compared with placebo decreases pain perception in patients undergoing cardiac
surgery in the first 24 hours and 2 months after hospital discharge; evaluate analgesic
consumption in the immediate postoperative period; evaluate differences in blood gas
parameters between groups; evaluate anesthetic recovery by QoR-40; assess incidence of
serious adverse events (reintubation and mental confusion); incidence of delirium through the
CAM-ICU questionnaire; assess adverse drug events (nausea, vomiting, pharmacodermia, allergic
reactions). METHOD: Randomized, triple-blind, placebo-controlled clinical trial. EXPECTED
RESULTS: Postoperative pain control with a drug that could cause fewer side effects, may lead
to faster clinical improvement, fewer medications and fewer procedures, and lower healthcare
costs with a decrease in intensive care unit (ICU) stay.